Jury Awards Guardant Health $292.5M in False-Advertising Lawsuit Against Natera

Dow Jones2024-11-26

By Connor Hart

A jury awarded Guardant Health $292.5 million in damages related to a false-advertising and unfair-competition lawsuit that the oncology company brought against rival Natera in 2021.

The decision, which includes $175.5 million in punitive damages, represents what Guardant Health on Monday called one of the largest false advertising verdicts in history.

The jury found that Austin, Texas-based Natera engaged in a deliberate campaign to mislead cancer clinicians about Guardant Reveal, the Palo Alto, Calif., company's early-stage colorectal cancer test, in favor of Natera's competing product.

Natera said it disagrees with the jury's decision and will ask the court to overturn it.

"The jury was asked to evaluate comparative advertisements that ran for a brief period in 2021 related to the performance of Guardant's Reveal test," the company said. "This case had nothing to do with the validity or utility of Signatera and certain key pieces of evidence supporting Natera's case were not included in this trial."

Signatera is Natera's competing cancer test to Reveal.

Guardant Health Chief Legal Officer John Saia celebrated the jury's decision. "Today's unanimous verdict holding Natera responsible for engaging in illegal and anticompetitive conduct represents a major victory for colorectal cancer patients who could benefit from our groundbreaking Reveal test," he said.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

November 25, 2024 17:45 ET (22:45 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2486617630?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-26 06:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2486617630","market":"other","top_or_hot":-1,"title":"Jury Awards Guardant Health $292.5M in False-Advertising Lawsuit Against Natera","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre>\n \n</pre>\n<p>\n  A jury awarded Guardant Health $292.5 million in damages related to a false-advertising and unfair-competition lawsuit that the oncology company brought against rival Natera in 2021. \n</p>\n<p>\n  The decision, which includes $175.5 million in punitive damages, represents what Guardant Health on Monday called one of the largest false advertising verdicts in history. \n</p>\n<p>\n  The jury found that Austin, Texas-based Natera engaged in a deliberate campaign to mislead cancer clinicians about Guardant Reveal, the Palo Alto, Calif., company's early-stage colorectal cancer test, in favor of Natera's competing product. \n</p>\n<p>\n  Natera said it disagrees with the jury's decision and will ask the court to overturn it. \n</p>\n<p>\n  \"The jury was asked to evaluate comparative advertisements that ran for a brief period in 2021 related to the performance of Guardant's Reveal test,\" the company said. \"This case had nothing to do with the validity or utility of Signatera and certain key pieces of evidence supporting Natera's case were not included in this trial.\" \n</p>\n<p>\n  Signatera is Natera's competing cancer test to Reveal. \n</p>\n<p>\n  Guardant Health Chief Legal Officer John Saia celebrated the jury's decision. \"Today's unanimous verdict holding Natera responsible for engaging in illegal and anticompetitive conduct represents a major victory for colorectal cancer patients who could benefit from our groundbreaking Reveal test,\" he said. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 25, 2024 17:45 ET (22:45 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jury Awards Guardant Health $292.5M in False-Advertising Lawsuit Against Natera</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJury Awards Guardant Health $292.5M in False-Advertising Lawsuit Against Natera\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-11-26 06:45</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre>\n \n</pre>\n<p>\n  A jury awarded Guardant Health $292.5 million in damages related to a false-advertising and unfair-competition lawsuit that the oncology company brought against rival Natera in 2021. \n</p>\n<p>\n  The decision, which includes $175.5 million in punitive damages, represents what Guardant Health on Monday called one of the largest false advertising verdicts in history. \n</p>\n<p>\n  The jury found that Austin, Texas-based Natera engaged in a deliberate campaign to mislead cancer clinicians about Guardant Reveal, the Palo Alto, Calif., company's early-stage colorectal cancer test, in favor of Natera's competing product. \n</p>\n<p>\n  Natera said it disagrees with the jury's decision and will ask the court to overturn it. \n</p>\n<p>\n  \"The jury was asked to evaluate comparative advertisements that ran for a brief period in 2021 related to the performance of Guardant's Reveal test,\" the company said. \"This case had nothing to do with the validity or utility of Signatera and certain key pieces of evidence supporting Natera's case were not included in this trial.\" \n</p>\n<p>\n  Signatera is Natera's competing cancer test to Reveal. \n</p>\n<p>\n  Guardant Health Chief Legal Officer John Saia celebrated the jury's decision. \"Today's unanimous verdict holding Natera responsible for engaging in illegal and anticompetitive conduct represents a major victory for colorectal cancer patients who could benefit from our groundbreaking Reveal test,\" he said. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 25, 2024 17:45 ET (22:45 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4196","symbol_name":"保健护理服务","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2486617630","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2486617630","pubTimestamp":1732574700,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"A jury awarded Guardant Health $292.5 million in damages related to a false-advertising and unfair-competition lawsuit that the oncology company brought against rival Natera in 2021.The decision, which includes $175.5 million in punitive damages, represents what Guardant Health on Monday called one of the largest false advertising verdicts in history.The jury found that Austin, Texas-based Natera engaged in a deliberate campaign to mislead cancer clinicians about Guardant Reveal, the Palo Alto, Calif., company's early-stage colorectal cancer test, in favor of Natera's competing product.Natera said it disagrees with the jury's decision and will ask the court to overturn it.\"The jury was asked to evaluate comparative advertisements that ran for a brief period in 2021 related to the performance of Guardant's Reveal test,\" the company said. \"This case had nothing to do with the validity or utility of Signatera and certain key pieces of evidence supporting Natera's case were not included in","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4196":"保健护理服务","LU2065731478.USD":"ALLSPRING (LUX) WORLDWIDE FUND - SMALL CAP INNOVA \"I\" (USD) ACC","LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)","NTRA":"Natera, Inc.","GH":"Guardant Health Inc.","LU2065170008.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC","LU2065171311.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) ACC","BK4535":"淡马锡持仓","LU2065171402.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC","BK4551":"寇图资本持仓","BK4585":"ETF&股票定投概念","BK4139":"生物科技","LU2065169927.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC","BK4588":"碎股"},"translate_title":"陪审团在针对Natera的虚假广告诉讼中判给Guardant Health 2.925亿美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NTRA":1,"GH":0.9},"content_text":"By Connor Hart \n\n\n \n\n\n  A jury awarded Guardant Health $292.5 million in damages related to a false-advertising and unfair-competition lawsuit that the oncology company brought against rival Natera in 2021. \n\n\n  The decision, which includes $175.5 million in punitive damages, represents what Guardant Health on Monday called one of the largest false advertising verdicts in history. \n\n\n  The jury found that Austin, Texas-based Natera engaged in a deliberate campaign to mislead cancer clinicians about Guardant Reveal, the Palo Alto, Calif., company's early-stage colorectal cancer test, in favor of Natera's competing product. \n\n\n  Natera said it disagrees with the jury's decision and will ask the court to overturn it. \n\n\n  \"The jury was asked to evaluate comparative advertisements that ran for a brief period in 2021 related to the performance of Guardant's Reveal test,\" the company said. \"This case had nothing to do with the validity or utility of Signatera and certain key pieces of evidence supporting Natera's case were not included in this trial.\" \n\n\n  Signatera is Natera's competing cancer test to Reveal. \n\n\n  Guardant Health Chief Legal Officer John Saia celebrated the jury's decision. \"Today's unanimous verdict holding Natera responsible for engaging in illegal and anticompetitive conduct represents a major victory for colorectal cancer patients who could benefit from our groundbreaking Reveal test,\" he said. \n\n\n \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 25, 2024 17:45 ET (22:45 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.31.7","shortVersion":"4.31.7","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2486617630"}